Department of Pathology, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA.
Arch Pathol Lab Med. 2012 Jun;136(6):691-7. doi: 10.5858/arpa.2011-0168-RS.
Amplification of the human epidermal growth factor receptor 2/neu (HER2/neu) gene and overexpression of the HER2 protein (HER2) have been shown to occur in gastric and gastroesophageal junction adenocarcinoma in a number of studies. With a dismal survival rate, patients with these cancers stand to benefit from the identification of possible molecular targets such as HER2 for both prognostic and therapeutic purposes. Although these and other carcinomas that overexpress HER2 may have a poorer prognosis and exhibit resistance to conventional chemotherapy, they have also recently been shown to respond to targeted therapy with the anti-HER2 antibody trastuzumab. Here, we briefly review the molecular biology, histopathology, diagnostic techniques, and interpretation, as well as the clinical implications, of HER2 amplification/overexpression in gastric and gastroesophageal adenocarcinoma.
在许多研究中已经证实，人类表皮生长因子受体 2/neu（HER2/neu）基因的扩增和 HER2 蛋白的过表达发生在胃和胃食管交界处腺癌中。这些癌症患者的生存率令人沮丧，因此需要确定可能的分子靶点，如 HER2，以用于预后和治疗目的。尽管这些和其他过表达 HER2 的癌可能具有更差的预后并表现出对常规化疗的耐药性，但最近也已经显示它们对曲妥珠单抗等抗 HER2 抗体的靶向治疗有反应。在这里，我们简要回顾了 HER2 扩增/过表达在胃和胃食管腺癌中的分子生物学、组织病理学、诊断技术和解释以及临床意义。
